CNMD vs UNH

CNMD exhibits a stark divergence between its strong balance sheet health (Piotroski F-Score: 7/9) and its deteriorating operational performance. While the company maintains a stable financial foundation and a low Price-to-Sales ratio, it is plagued by a severe earnings collapse (-50% YoY) and a consistent track record of missing analyst estimates (0/4 beats in the last year). With the current price ($38.34) trading above the Graham Number ($33.66) and significantly above the growth-based intrinsic value ($10.57), the stock lacks a valuation catalyst despite a low forward P/E.

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.